Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable...
01.06.2012
- Sanofi aims to build on its diabetes portfolio, which has so far relied on blockbuster insulin Lantus, with a wider range of treatments that could address not just the disease but...
